|Mr. Michael S. Weiss||Exec. Chairman||60k||N/A||1966|
|Dr. Manuel Litchman||Pres, CEO & Director||605.51k||N/A||1954|
|Mr. Brian K. Achenbach||Sr. VP of Fin. & Corp. Controller||301.01k||N/A||1965|
|Dr. Knut Niss||Chief Technology Officer||N/A||N/A||N/A|
|Ms. Debra Manning||VP of HR||N/A||N/A||N/A|
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase I/II clinical trials. The company also develops CD123, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; CD20 for immunotherapy of B-cell lymphomas; CS1, an NK cell receptor regulating immune functions; IL13Ra2 CAR T cell program for glioblastoma; HER2 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; and PSCA CAR T for prostate and pancreatic cancers. It has a license agreement with Harvard University for the treatment of cancer; Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
Mustang Bio, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 2; Compensation: 7.